(29 days)
No
The description focuses on photometric techniques and physical characteristics, with no mention of AI or ML.
No
The device is a measurement cell that is part of a system used to measure oxygen saturation and hematocrit in an extracorporeal circuit. It does not directly treat or prevent a disease or condition.
Yes
The device measures physiological parameters (oxygen saturation and hematocrit) within an extracorporeal circuit, which are used to monitor a patient's condition and inform medical decisions, fitting the definition of a diagnostic device.
No
The device description clearly states it is a "single-use insert" and a "disposable device" that accommodates the transmission and collection of light signals, indicating it is a physical hardware component.
Based on the provided text, the Trillium™ Tri-optic Measurement Cell is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use states it's for use in the BioTrend oxygen saturation and hematocrit system, which measures these parameters in the extracorporeal circuit. This means it's measuring components of blood outside the body, within a medical device system.
- Device Description: The description reinforces this by stating it's an "in-line, full flow, sterile and non-pyrogenic fluid path disposable device" that accommodates light transmission and collection into the blood path. This is consistent with a device used within an extracorporeal circuit.
- Lack of IVD Characteristics: The description does not mention analyzing samples in vitro (in a test tube or lab setting) to diagnose a condition or disease. It's a component of a system that measures physiological parameters in real-time within a medical procedure.
Therefore, the Trillium™ Tri-optic Measurement Cell is a component of a medical device used in extracorporeal circuits, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Trillium™ Tri-optic Measurement Cell is intended for use in the BioTrend oxygen saturation and hematocrit system.
Indications for Use:
The BioTrend oxygen saturation and hematocrit system measures percent oxygen saturation and hematocrit of the blood in the extracorporeal circuit. The extracorporeal circuit is used for, but is not limited to, cardiopulmonary bypass, closed chest support and limb perfusion.
Product codes (comma separated list FDA assigned to the subject device)
DRY
Device Description
The Trillium™ Tri-optic Measurement Cell is a single-use insert designed to be used in the BioTrend Qxygen Saturation and Hematocrit System (K954501). The BioTrend Oxygen Saturation and Hematocrit System measures oxygen saturation and hematocrit by using dual wavelength photometric techniques. The Tri-optic Measurement Cell is an in-line, full flow, sterile and non-pyrogenic fluid path disposable device. The device accommodates the transmission of the light-emitting signal into the blood path and collection of the backscattered light signal.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The biocompatibility and in vitro bench testing demonstrated that when compared to the predicate devices, the Trillium™ Tri-optic Measurement Cell does not significantly affect safety and effectiveness and are substantially equivalent to other commercially distributed extracorporeal cardiopulmonary devices.
The in vitro bench testing included analysis of:
Coating Characteristics
Physical Characteristics
Performance Characteristics
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4330 Cardiopulmonary bypass on-line blood gas monitor.
(a)
Identification. A cardiopulmonary bypass on-line blood gas monitor is a device used in conjunction with a blood gas sensor to measure the level of gases in the blood.(b)
Classification. Class II (performance standards).
0
SUMMARY OF SAFETY AND EFFECTIVENESS
COMPANY AND CONTACT PERSON
Medtronic Perfusion Systems 7611 Northland Drive Minneapolis, MN 55428 (763) 391-9183 Tel: FAX: (763) 391-9603
Marie L. Holm, Associate Product Regulations Manager, Regulatory Affairs
DEVICE NAME
Trillium™ Tri-optic Measurement Cell
name of predicated or legally marketed device
Tri-optic Measurement Cell (K910421) 117 Splio Mousuremonor with Trillium™ Biopassive Surfaçe (K973760)
DESCRIPTION OF DEVICE
The Trillium™ Tri-optic Measurement Cell is a single-use insert designed to be used in the BioTrend Qxygen Saturation and Hematocrit System (K954501). The BioTrend Oxygen Saturation and Hematocrit System measures oxygen saturation and hematocrit by using dual wavelength photometric techniques. The Tri-optic Measurement Cell is an in-line, full flow, sterile and non-pyrogenic fluid path disposable device. The device accommodates the transmission of the light-emitting signal into the blood path and collection of the backscattered light signal.
STATEMENT OF INTENDED USE
The Trillium™ Tri-optic Measurement Cell is to be used with the BioTrend Oxygen Saturation and Hematocrit System.
The BioTrend Oxygen Saturation and Hematocrit System measures percent oxygen saturation and hematocrit of the blood in the extracorporeal circuit. The extracorporeal circuit is used for, but is not limited to, cardiopulmonary bypass, closed chest support and limb perfusion
STATEMENT OF INTENDED USE OF PREDICATED/MARKETED DEVICE
The Tri-optic Measurement Cell is to be used with the BioTrend Oxygen Saturation and Hematocrit System.
The BioTrend Oxygen Saturation and Hematocrit System measures percent oxygen saturation and hematocrit of the blood in the extracorporeal circuit. The extracorporeal circuit is used for, but is not limited to, cardiopulmonary bypass, closed chest support and limb perfusion
Special 510(k) Notification Medtronic, Inc. Medtronic Perfusion System Trillium™ Tri-optic Measurement Cell
Confidential
1
STATEMENT OF TECHNOLOGICAL CHARACTERISTICS COMPARISON
Information regarding technological characteristics comparison is provided in the following section, "Determination of Substantial Equivalence".
DETERMINATION OF SUBSTANTIAL EQUIVALENCE
This "SPECIAL 510(k)" is being submitted for a modification to the Tri-optic Measurement Cell. The modification to the current Tri-optic Measurement Cell is to coat the blood contact surfaces with Trillium""
The Trillium™ Tri-optic Measurement Cell is being compared to the following marketed devices:
- Tri-optic Measurement Cell (K910421) .
- AFFINITY® Hollow Fiber Oxygenator with Trillium™ Biopassive Surface . (K973760)
The Trillium™ Tri-optic Measurement Cell has the same indications statement and intended uses as the:
-
Tri-optic Measurement Cell (K910421) .
The Trillium" Tri-optic Measurement Cell has "no new technological characteristics (e.g., materials and manufacturing processes)" from the Tri-optic Measurement Cell. The technological characteristic is solely the coating material of the blood pathway: -
Trillium™ .
The technological characteristic of the Trillium™ Biopassive Surface is common to other medical devices (hollow fiber oxygenators) currently in commercial distribution as follows: -
AFFINITY® Hollow Fiber Oxygenator with Trillium™ Biopassive Surface . (K973760)
This technological characteristic "could affect the safety and effectiveness of the device". However, these "technological characteristics do not raise new types of safety or effectiveness questions". In addition, "there are acceptable scientific methods which exist for assessing effects of these new technological characteristics".
"Performance data to assess the effects of these new technological characteristics" has been performed. These "performance data demonstrate" that the Trillium" Tri-optic Measurement Cell is substantially equivalent to other marketed extracorporeal cardiopulmonary bypass devices.
Confidential
2
The biocompatibility and in vitro bench testing demonstrated that when compared to the predicate devices, the Trillium™ Tri-optic Measurement Cell does not significantly affect safety and effectiveness and are substantially equivalent to other commercially distributed extracorporeal cardiopulmonary devices.
The in vitro bench testing included analysis of:
Coating Characteristics
Physical Characteristics
Performance Characteristics
Special 510(k) Notification Medtronic, Inc. Medtronic Perfusion System Confidential
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is a stylized symbol featuring three abstract human profiles facing to the right, stacked one behind the other.
Public Health Service
SEP 1 4 2001
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ms. Marie L. Holm Medtronic Perfusion Systems 7611 Northland Drive N Minneapolis, MN 55428-1088
Re: K012743
Trade Name: Trillium™ Tri-optic Measurement Cell (TMC 25T, 38T, and 50T) Regulation Number: 21 CFR 870.4330 Regulation Name: Monitor, blood gas, on-line, cardiopulmonary bypass Regulatory Class: Class II (two) Product Code: DRY Dated: August 15, 2001 Received: August 16, 2001
Dear Ms. Holm:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 – Ms. Marie L. Holm
Please be advised that FDA's issuance of a substantial equivalence determination does not mean Flease be advised that I Dri 3 issuation of our device complies with other requirements of the Act that I Dri has made a acternmentations administered by other Federal agencies. You must of ally reachardies and regulations and with the be registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set CTN Part 607), adomig (21 OFR Part 820); and if applicable, the electronic forth in the quality bybellions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) This letter will and w you to over finding of substantial equivalence of your device to a legally prematication: "The Prodication for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of adultionally 21 OF For and 646. Additionally, for questions on the promotion and advertising of Compliance at (301) 594-461 the Office of Compliance at (301) 594-4639. Also, please note the your de revels, "Misbranding by reference to premarket notification" (21CFR Part 807.97). regulation entires, "Thison on your responsibilities under the Act may be obtained from the Oiner general missimal Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
James E. Dillard III Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510 (k) Number if known: K0112743 -
Device Name: Trillium™ Tri-optic Measurement Cell
The Trillium™ Tri-optic Measurement Cell is intended for use in the BioTrend oxygen saturation and hematocrit system.
Indications for Use:
The BioTrend oxygen saturation and hematocrit system measures percent The Blor rond oxygen saturation in the extracorporeal circuit. The extracorporeal circuit is used for, but is not limited to, cardiopulmonary bypass, closed chest support and limb perfusion.
Concurrence of CDRH, Office of Device Evaluation (ODE)
Division of Cardiovascular & Respiratory Devices
510(k) Number: K0(2743
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter use